Press Release
23 Mar, 2020
On March 23, 2020, InnoCare (Hong Kong Stock Exchange Code: 09969) was officially listed on the main board of The Stock Exchange of Hong Kong Limited (Hong Kong Stock Exchange). InnoCare issued 250, 324,000 shares worldwide at HK $ 8.95 per share, raising approximately HK $ 2.24 billion. The company intends to use raised proceeds primarily for the company's core drug candidates, clinical development of other drug candidates in the pipeline, marketing authorization and external introduction of new projects, etc., and begin the commercialization process and layout of products. InnoCare focuses on two major therapeutic areas, cancers and autoimmune diseases, that have significant market opportunities and synergistic benefits. In less than five years, guided by the global vision of the management team, Innocare has achieved many great milestones, including the discovery and development nine Drug candidates, the submission of 2 NDA applications for core drug candidate ,Orelabrutinib (ICP-022), progressing the second and third drug candidates through Phase I / II clinical trials, and the IND application submission for the fourth drug candidate. These drugs have the potential to meet the huge, unmet, medical needs and benefit patients worldwide. InnoCare has been favored by many well-known investment institutions in the several rounds of financing so far, with its core competitiveness in research and development, balanced drug pipelines, and excellent teams. InnoCare co-founder, chairman and CEO Dr. Cui Jisong said: "Listing on the Hong Kong Stock Exchange marks a new era for InnoCare! In January of this year (2020), InnoCare was happy to report that the NDA for Orelabrutinib was included in the priority review by the NMPA. We are also happy to report that the new indication for Orelabrutinib was also accepted by the NMPA earlier this month. InnoCare was listed on the Hong Kong Stock Exchange today is also the first IPO of a biopharmaceutical company on the HKEX in 2020. This not only reflect the strong cohesion and execution of our team, but also a powerful demonstration of InnoCare's strong commitments. We were honored and heartened to hear the listing bell. Thank you for your recognition, affirmation and support of InnoCare from all walks of life. Starting from this, we will continue to make great strides on the road of innovative research and development, and we are committed to developing and providing innovative therapies for patients around the world, providing growth opportunities for our employees, creating value for shareholders, and shouldering more social responsibilities! "
06 Mar, 2020
InnoCare announced that the National Medical Products Administration of China (NMPA) has accepted Orelabrutinib (ICP-022) for the new drug application (NDA) for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL). Orelabrutinib was independently developed by InnoCare's team and is used to treat a variety of B-cell malignancies, including cancers and autoimmune diseases. It is currently undergoing extensive clinical research in China and the United States. InnoCare co-founder, chairman and CEO Dr. Cui Jisong said: " This is the second new drug listing application accepted by the NMPA for Orelabrutinib, and is another important milestone achieved in a short period of time after the first NDA of Orelabrutinib was included in the priority review in January this year. Orelabrutinib's international multi-center clinical data has become increasingly abundant, and the company's commercialization team is also under rapid construction. I have full confidence that Orelabrutinib will benefit patients with clinical needs worldwide. " The NDA is based on data from a clinical trial: A Phase I/II Clinical study to investigate the safety, tolerability and pharmacokinetics/pharmacodynamics of ICP-022 in Chinese patients with relapsed/refractory mantle cell lymphoma (MCL) (Registration No. CTR20180196). Previously, the NDA for Orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) was accepted by the NMPA in November 2019 and included in January 2020 Priority review. As part of a global development project, a number of clinical studies on Orelabrutinib are currently underway. In addition to the above-mentioned indications for NDA submission, relapse/refractory marginal zone lymphoma (MZL), relapse/refractory central nervous system lymphoma (CNSL), relapse/refractory macroglobulinemia (WM), relapse/refractory CD20 + B-cell lymphoma relapse/refractory diffuse large B-cell lymphoma (DLBCL) and clinical studies of patients with mild to moderate systemic lupus erythematosus (SLE) also conducted in China ; in addition to a Phase I trial for B-cell malignancies, which was approved by the U.S. Food and Drug Administration (FDA) in May 2019.
13 Jan, 2020
On January 13, 2020, InnoCare announced that the National Drug Administration of China (NMPA) Drug Evaluation Center (CDE) has prioritized the new drug application (NDA) for Orelabrutinib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL). InnoCare co-founder, chairman and CEO Dr. Cui Jisong said: " We are very encouraged by the inclusion of Orelabrutinib in the priority review category.. This fully demonstrates the country's determination to encourage innovation and accelerate the launch of new drugs, so that Chinese patients will have access to international first-in-class new drugs as soon as possible. We will accelerate the market launch of Orelabrutinib and expand its indications to meet the urgent clinical needs of patients world-wide. " Orelabrutinib's NDA for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) was accepted by the NMPA in November 2019. This NDA was submitted based on data from a clinical trial: A Phase I/II clinical study to investigate the safety, tolerability and pharmacokinetics/pharmacodynamics of ICP-022 in Chinese patients with relapsed/refractory chronic lymphoblastic leukemia (CLL)/small lymphoblastic lymphoma (SLL) (Registration No. CTR20180263). A number of global clinical studies on Orelabrutinib are ongoing. The purpose of drug priority review is to accelerate the development and marketing of clinically needed drugs with significant therapeutic advantages. The national drug administration department will prioritize the review and verification of these urgently needed drugs.
20 Nov, 2019
On November 20, 2019, InnoCare announced that the NMPA has accepted the NDA of Orelabrutinib (ICP-022) for the treatment of patients with r/r CLL/SLL.
05 Oct, 2019
InnoCare announced that it will present clinical data on its investigational BTK inhibitor Orelabrutinib (ICP-022) at the 61st ASH Annual Meeting, Dec. 7-10 in USA.
01 Oct, 2019
InnoCare announced that Dr. Xiangyang Chen, who has over 20 years’ experience in biomedical research, was promoted to CTO.
03 Jun, 2019
InnoCare, a leading innovator for global biopharmaceutical drugs, is proud to announce the appointment of Shaojing Tong as Chief Financial Officer (CFO). Mr. Tong has been a leading healthcare research analyst for the Asia-market and has extensive knowledge of the industry. Reporting directly to the CEO, Dr. Jasmine Cui, Mr. Tong will be responsible for the financial strategy development, risk management, and investment analysis. Mr. Tong is considered one of Hong Kong’s top research analysts for the entire biopharmaceutical and healthcare sector, repeatedly being ranked in the “Best Analyst Team” of the Asian healthcare industry. Mr. Tong has many years of experience in managing investment analyst teams and has acquired comprehensive knowledge of the industries history, value chains, and developmental trends. Before joining InnoCare, Mr. Tong served as an executive director and industry analyst at UBS China, where he covered medical companies for both the Hong Kong and A-class China markets. Prior to UBS, Mr. Tong was a healthcare research analyst for Bank of America Merrill Lunch (Hong Kong) and Michael Partners (New York). Preceding his financial career, Mr. Tong worked in drug development for CADUS Pharmaceuticals (New York). Mr. Tong received a Bachelor of Science degree in materials science and engineering from the University of Science and Technology of China. He obtained a Master’s degree in chemistry at the University of Pittsburg, and a Master of Business Administration (MBA) from New York University. “We are very pleased to have Mr. Tong onboard,” said Dr. Cui, CEO and Chairman of InnoCare, “His extensive knowledge and unique insight of the biopharmaceutical industry will help cement a strong financial foundation for InnoCare so that we can continuously build towards our goal of becoming a global leader for innovative drugs.” “I am honored to be a member of InnoCare and work with such an outstanding team,” Mr. Tong said, “InnoCare is a leader among Chinese innovative pharmaceutical companies, establishing a wealth of product pipeline in a very short amount of time. I look forward to joining such an experienced and passionate team, and will advance InnoCare’s goal of providing safe, effective, and affordable drugs for patients around the world.”
09 May, 2019
On May 9th of 2019, InnoCare announced the approval of their proprietary BTK inhibitor ICP-022 by the US Food and Drug Administration (FDA) for initiation of clinical investigations. ICP-022 is the first innovative drug candidate from InnoCare to initiate clinical trials in the US. ICP-022 is a highly selective BTK inhibitor targeting both oncology and autoimmune indications. Currently multi-center, multi-indication phase I/II studies are underway in China, with encouraging preliminary results on safety and efficacy. Following the IND approval, InnoCare will soon conduct the clinical trials in the US for ICP-022. InnoCare will also actively seek collaborations with innovative biotech and pharmaceutical companies in related areas. “This is a major milestone for us. We are fully committed to the global development of ICP-022 and looking forward to the expansion of ICP-022 into global markets.” said Dr. Cui Jisong, co-founder, Chairman, and CEO of InnoCare.
11 Mar, 2019
March 11, 2019, InnoCare announced that Mr. James Deng has accepted the invitation to be its ABM in Sales & Marketing,providing consultancy on launch strategy and commercial operation. As a member of BD Global Operating Committee, Mr. James Deng is the Senior Vice President of BD and General Manager of Greater China. He is also the founding and elected AdvaMed China Board Chair for four consecutive terms. Prior to BD, Mr. James Deng served as VP Marketing in Novartis Pharma US. Before that, he was the CEO & President for Novartis Pharma China, leading Novartis  to be the largest multinational pharmaceutical company with the fastest growing business in China. Under his leadership, the “thick product project” he initiated to optimize the company's infrastructure significantly improved the company's competitiveness. This project was selected as a classic case of Harvard Business School. Mr. James Deng also worked for Johnson & Johnson Pharma in China. He is a graduate of China Europe International Business School (CEIBS) EMBA and General Management Program(GMP) of Harvard Business School. Mr. James Deng now takes active role as Deputy Head of Healthcare Industry Division in China Health Economics Association. “It’s our privilege to have Mr. James Deng to be a key member in InnoCare’s Advisory Board in Sales & Marketing.” Said Dr. Jasmine Cui, Chairman and CEO of InnoCare,” James is a highly respected leader in healthcare industry. His track-record in leading multinational pharma and MedTech companies is resulted from his profound market insights, strong business operation, and global perspective. James’ support will accelerate the pace of InnoCare’s innovative drug products reaching the patients with urgent needs”. “I am truly honored to be a member of InnoCare’s advisory board. As someone who has been working in healthcare for 30years, I have two missions: one is always putting the patient in the center of everything we do, bringing real benefits to them; one is driving true China innovation that can make a global impact. As a leading innovative company in China, InnoCare has done an excellent job in these two aspects. I will contribute as much as I can to support InnoCare become one of the most successful organization in both drug R&D and  commercialization. I believe by doing so, together, we will greatly benefit patients in China and worldwide”.
20 Jul, 2018
On July 20, 2018, InnoCare announced an agreement between Beijing InnoCare Pharma Tech Co., Ltd., Guangzhou Development Zone, and its subsidiary Guangzhou Kaide Technology Development Co., Ltd. (Kaide Technology) to establish Guangzhou InnoCare Pharma Tech Co., Ltd., a development center with advanced international standards. Dr. Jisong Cui, co-founder, Chairman, and CEO of InnoCare, said: “We are very pleased to establish the InnoCare Guangzhou Development Center with the Guangzhou Development Zone. It is an important milestone for InnoCare to expand from R&D to manufacture. With China’s aging population, we are in urgent need of more innovative therapies for cancer and autoimmune diseases. The establishment of the InnoCare Guangzhou Development Center will accelerate InnoCare’s innovation in developing more effective and affordable medicines for China and the world.” With a total investment of over 2 billion RMB, the Guangzhou Development Center will cover about 20 acres. Its design, which will meet the GMP requirements of US, Europe, and China, will support InnoCare’s needs from clinical trials to commercial production. The head of the Guangzhou Development Zone Management Committee said: “Guangzhou will further improve and expand the landscape of the biomedical industry. The successful establishment of InnoCare’s facility is of great importance to us and will help Guangzhou build a world-class innovative pharmaceutical industrial cluster. Guangzhou, in-line with the rapid development of InnoCare, will give its strong support to all aspects including fund-raising, management services, and creating a prolific business environment. About InnoCare InnoCare is an emerging biotech company focused on the innovation of novel drugs for immuno-oncology/targeted therapy and autoimmune diseases. Though rooted in China, InnoCare’s mission is to become a global leader in providing patients with safe, effective, and affordable treatments for cancer and autoimmune diseases. Autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, have high incidence in the China and lack effective treatments. InnoCare combines internal R&D, licensing-in, and international collaboration to drive the development of Best-in-Class drugs. About Guangzhou Kaide Technology Development Co., Ltd. Founded in 1998, Guangzhou Kaide Technology Development Co., Ltd. is a wholly state-owned company under the Guangzhou Development Zone. As the largest technology strategic shareholding platform in the Guangzhou Development Zone, Kaide Technology Co., Ltd. invests in “IAB” and “NEM” industrial projects, such as high-tech enterprises and advanced manufacturing industries. At present, Kaide Technology’s portfolio includes Lejin Display (China) Co., Ltd., BeiGene Bio-Pharmaceutical Co., Ltd., and Xintongyuan Industrial Internet Innovation Center (Guangdong) Co., Ltd. As the director unit of Guangzhou Urban Block Chain Industries, Kaide Technologies will facilitate the development of Guangdong’s block chain industry.